Analysis of the multi-drug resistant tuberculosis treatment outcomes: Experience from the special hospital for pulmonary diseases "Ozren"

Analysis of the multi-drug resistant tuberculosis treatment outcomes: Experience from the special hospital for pulmonary diseases "Ozren" - Sokobanja

Published:2024 Issue:1 Volume:98 Page:33-50
ISSN:2812-7552
Container-title:Glasnik javnog zdravlja
language:en
Short-container-title:Glas javnog zdr

Author:

Antonijević Gordana,Stošić Maja^ORCID

Abstract

Multidrug-resistant tuberculosis (MDR TB) is currently considered to be the most significant and dangerous obstacle to the TB elimination, and the work on preventing this form of disease is considered as a major contribution to human health and resource management. The purpose of the article is to analyse treatment outcomes in patients treated for multiresistant tuberculosis at the Special Hospital for Pulmonary Diseases "Ozren" - Sokobanja in the period from 2009 to 2019 and identify factors associated with treatment outcomes. We performed a retrospective analysis of the treatment outcomes in all (n=89) cases of MDR TB treated over the period from 2009-2019 at the Special Hospital for Pulmonary Diseases Ozren - Sokobanja. Descriptive statistical analysis of all available MDR TB characteristics was used. Logistic regression analysis was used to identify factors associated with successful treatment (treatment outcomes "cured" and "treatment completed") and mortality. Patient mortality was statistically significantly associated with undernutrition (OR = 5.55; 95% CI: 1.39-20.00), alcohol consumption (OR = 4.54; 95% CI: 1.22-10.67), bilateral cavitary lesions (OR = 16.67; 95% CI: 3.03-100.00), multiple prior treatment episodes (p<0.001), longer time to diagnosis (p<0.001), higher average number of hospitalizations and previous treatment episodes (p<0.001), and the following comorbidities: pulmonary (OR = 14.29; 95% CI: 2.70-100.00), cardiovascular diseases (OR = 7.14; 95% CI: 1.79-25.00), diabetes (OR = 5.88; 95% CI: 1.39-25.00) and malignant diseases (OR = 12.50; 95% CI: 1.85-100.00). The success of MDR TB treatment is very good. To maintain and further improve this success, it is necessary to focus interventions on resolving social issues and comorbidities among patients from risk groups associated with poor treatment outcomes, as well as on education of health professionals related to suspicion of TB, its recognition and referral to specialized institutions for MDR TB diagnostics and treatment.

Publisher

Centre for Evaluation in Education and Science (CEON/CEES)

Link

https://scindeks-clanci.ceon.rs/data/pdf/2812-7552/2024/2812-75522401033A.pdf

Reference32 articles.

1. World Health Organisazion. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: WHO; c2014. 452p. Ref. No: WHO/HTM/TB/2014.11. ISBN: 978-92-4-154880-9;

2. Rebić P, Kuruc V, Ćurčić R, Savic B. Priručnik za ambulantno lečenje obolelih od rezistentne tuberkuloze. [Handbook for ambulatory treatment of patients with multy-resistant tuberculosis]. Belgrade:Ministarstvo zdravlja Republike Srbije; 2011. 69p. ISBN: 978-86-83607-62-4. Serbian;

3. World Health Organization. WHO Consolidated Guidelines on Drug-Resistant Tuberculosis Treatment. Geneva:WHO; c2019. 120p. Ref. No: WHO/CDS/TB/2019.7. ISBN: 978-92-4-155052-9.;

4. World Health Organisazion. Guidelines for programmatic management of drug-resistant tuberculosis: 2011 update. Geneva: WHO; 2011. 44p. Ref. No: WHO/HTM/TB/2011.6. ISBN: 978-92-4-150158-3;

5. Radosavljević-Ašić G, Rebić P, Pavlović S, Kuruc V, Savić B, Jevtović Đ, et al. Revidirano stručno metodološko uputstvo za sprečavanje i suzbijanje tuberkuloze u Republici Srbiji. [Guidelines for tuberculosis management and control in the Republic of Serbia]. Belgrade: Ministry of Health of the Republic of Serbia; 2009. 90p. ISBN 978-86-83607-46-4. Serbian.;